Home > Insider Trading > Filing (0001615774-17-003457)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1430306	Tonix Pharmaceuticals Holding Corp.	TNXP	Pharmaceutical Preparations (2834)	261434750

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563420	Seth Lederman	C/O Tonix Pharmaceuticals Holding Corp 509 Madison Ave., Suite 306 New York NY 10022	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Acquisiton	2017-06-30	5,000	$4.33	30,000	No	4	P	Indirect	By IRA account

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By IRA account

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	13,300	Indirect	By 401(k) plan
Common Stock, $0.001 Par Value	7,912	Direct
Common Stock, $0.001 Par Value	3,100	Indirect	By spouse
Common Stock, $0.001 Par Value	3	Indirect	By Leder Laboratories, Inc.
Common Stock, $0.001 Par Value	2,917	Indirect	By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 Par Value	18,463	Indirect	By Lederman & Co., LLC
Common Stock, $0.001 Par Value	3,246	Indirect	By L&L Technologies, LLC
Common Stock, $0.001 Par Value	5,898	Indirect	By Targent Pharmaceuticals, LLC

Footnotes

The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.32797964. The range of purchase prices on the transaction date was $4.3123 to $4.35 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
Reporting person may be deemed to be a control person of this entity.